🔗 Permalink

Inventor profile of:

Corey Bloom

City:

Bend, Oregon

Country:

United States

Published Applications:

Last publication date:

2026-03-26

Top Assignees for applications by Corey Bloom

The entities that hold a legal rights for patent applications filed by inventor Bloom Corey:

Deciphera Pharmaceuticals, LLC 20 Waltham, MA United States
Glialogix, Inc. 2 Sunnyvale, CA United States
BRISTOL-MYERS SQUIBB COMPANY 1 Princeton, NJ United States
ONXEO 1 Paris, France

Recent patent applications by Bloom Corey

Corey Bloom from Bend, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-26

US20260083734A1

Human necessities

DOSAGE FORMS FOR TYK2 INHIBITORS

#2 | 2026-03-26

US20260083733A1

Human necessities

DOSAGE FORMS FOR TYK2 INHIBITORS

#3 | 2025-12-25

US20250387380A1

Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#4 | 2024-11-28

US20240390345A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#5 | 2024-11-28

US20240390344A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#6 | 2024-11-28

US20240390343A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#7 | 2024-10-24

US20240350466A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#8 | 2024-06-20

US20240197696A1

Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#9 | 2024-05-09

US20240148706A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#10 | 2024-04-18

US20240122907A1

Human necessities

(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#11 | 2024-03-21

US20240091206A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#12 | 2024-02-29

US20240066013A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#13 | 2024-02-29

US20240066012A1

Human necessities

COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA

#14 | 2023-12-07

US20230390258A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#15 | 2023-12-07

US20230390257A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#16 | 2023-12-07

US20230390256A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#17 | 2023-12-07

US20230390255A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea

#18 | 2023-08-31

US20230270728A1

Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#19 | 2023-08-17

US20230255964A1

Human necessities

EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS

#20 | 2023-06-29

US20230201176A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#21 | 2023-06-29

US20230201175A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#22 | 2022-10-20

US20220331315A1

Human necessities

DOSAGE FORMS FOR TYK2 INHIBITORS

#23 | 2022-08-25

US20220265623A1

Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#24 | 2022-08-25

US20220265622A1

Human necessities

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

#25 | 2022-08-18

US20220257574A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#26 | 2022-02-03

US20220031677A1

Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#27 | 2021-07-01

US20210196693A1

Human necessities

Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

#28 | 2021-07-01

US20210196692A1

Human necessities

Amorphous kinase inhibitor formulations and methods of use thereof

#29 | 2020-05-21

US20200155485A1

Human necessities

Oral formulations of belinostat

#30 | 2020-01-09

US20200009118A1

Human necessities

COMPOSITIONS AND METHODS FOR THE TREATMENTOF NEURODEGENERATIVE AND OTHER DISEASES

#31 | 2018-04-26

US20180110760A1

Human necessities

COMPOSITIONS AND METHODS FOR THE TREATMENTOF NEURODEGENERATIVE AND OTHER DISEASES

InventorID:

2169849 ⎘